ArticleAmerican journal of cancer research2026
Timing of spontaneous hepatocellular carcinoma rupture as a prognostic indicator.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic value of spontaneous ruptured hepatocellular carcinoma (rHCC) and its interaction with Barcelona Clinic Liver Cancer (BCLC) stages remain unclear. To assess the prognostic effects of rHCC and its interaction with BCLC staging. This was a retrospective cohort study enrolled 2,577 patients with hepatocellular carcinoma. rHCC was diagnosed using computed tomographic evidence of capsular disruption with extravasation of blood and classified as early or late according to whether rupture occurred ≤ 7 days or > 7 days after HCC diagnosis, respectively. Propensity score matching (PSM) was used to adjust for confounders. Cox proportional hazards regression models and Kaplan-Meier survival analyses were used to assess the prognostic effects of rHCC across BCLC stages. Of 2,577 patients, 102 (4.0%) had rHCC. Patients with rHCC were younger and had higher BCLC stages, worse liver function, and higher α-fetoprotein levels than those without rHCC. Multivariable Cox regression analysis revealed that late rHCC was a predictor of worse overall survival (OS; hazard ratio [HR]: 1.578, 95% confidence interval [CI]: 1.059-2.351) and that early rHCC was a protective factor (HR: 0.717, 95% CI: 0.519-0.992). A combination of early and late rupture did not predict OS. Kaplan-Meier analysis after PSM revealed that the OS for patients with early rHCC at BCLC stage B or C was similar to that for patients without rHCC (P = .594 for stage B and P = .566 for stage C) and that OS for patients with late rHCC at BCLC stage B or C was significantly worse than that for patients without rHCC (P = .007 for stage B and P = .006 for stage C). Late rHCC is associated with worse outcomes than early rHCC or nonruptured HCC at BCLC stages B and C.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.